BR0104830A - Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson - Google Patents

Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson

Info

Publication number
BR0104830A
BR0104830A BR0104830-9A BR0104830A BR0104830A BR 0104830 A BR0104830 A BR 0104830A BR 0104830 A BR0104830 A BR 0104830A BR 0104830 A BR0104830 A BR 0104830A
Authority
BR
Brazil
Prior art keywords
disease
parkinson
dementia
cognitive deficits
alzheimer
Prior art date
Application number
BR0104830-9A
Other languages
English (en)
Inventor
Stevin Howard Zorn
Anton Franz Josef Fliri
Mary Allen Sanner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0104830A publication Critical patent/BR0104830A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "TRATAMENTO DE COMBINAçãO PARA A DEMêNCIA OU DéFICITS COGNITIVOS ASSOCIADOS COM A DOENçA DE ALZHEIMER E COM A DOENçA DE PARKINSON". A invenção presente refere-se a um método de tratar a demência ou os déficits cognitivos associados com a doença de Aizheimer ou com a doença de Parkinson, em um mamífero, incluindo em um ser humano, pela administração ao mamífero de um receptor de dopamina D4 em combinação com um inibidor de acetilcolina esterase. Também refere-se a composições farmacêuticas que contenham um veículo farmaceuticamente aceitável, um receptor de dopamina D4 e um inibidor de acetilcolina esterase.
BR0104830-9A 2000-10-26 2001-10-26 Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson BR0104830A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24354300P 2000-10-26 2000-10-26

Publications (1)

Publication Number Publication Date
BR0104830A true BR0104830A (pt) 2002-05-28

Family

ID=22919160

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0104830-9A BR0104830A (pt) 2000-10-26 2001-10-26 Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson

Country Status (6)

Country Link
US (1) US20020052373A1 (pt)
EP (1) EP1201268A3 (pt)
JP (1) JP2003063994A (pt)
BR (1) BR0104830A (pt)
CA (1) CA2359877A1 (pt)
MX (1) MXPA01010872A (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
JP2004123562A (ja) * 2002-09-30 2004-04-22 Japan Science & Technology Corp 神経細胞死抑制作用を有する化合物を用いた医薬
CA2501547A1 (en) * 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7049307B2 (en) 2003-12-23 2006-05-23 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
BRPI0518693A2 (pt) * 2004-11-29 2008-12-02 Warner Lambert Co pirazol [3,4-b]piridinas e indazàis terapÊuticos, bem como composiÇço farmacÊutica e uso dos mesmos
JPWO2007126041A1 (ja) * 2006-04-28 2009-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゾイソオキサゾール化合物
KR101408454B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 착색을 억제하는 방법 및 도네페질의 친척 물질의 생성량을 감소시키는 방법
KR101442286B1 (ko) * 2006-12-01 2014-09-22 닛토덴코 가부시키가이샤 경피 흡수 제제
EP2078711A1 (en) * 2007-12-28 2009-07-15 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
US8008327B2 (en) * 2008-04-29 2011-08-30 Boehringer Ingelheim International Gmbh Indazole compounds as CCR1 receptor antagonists
CA2722811C (en) * 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
EP2279740A4 (en) * 2008-05-30 2011-12-14 Eisai R&D Man Co Ltd TRANSDERMAL PREPARATION
JP5208209B2 (ja) * 2008-05-30 2013-06-12 日東電工株式会社 ドネペジル含有貼付製剤およびその包装体
CN102227425A (zh) 2008-09-26 2011-10-26 贝林格尔·英格海姆国际有限公司 作为ccr1受体拮抗剂的氮杂吲唑化合物
AU2010302584B2 (en) 2009-10-02 2015-09-10 Avexxin As Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles
RS53130B (en) 2009-10-21 2014-06-30 Boehringer Ingelheim International Gmbh INDASOL AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
EP2493875B1 (en) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Heterocyclic compounds as ccr1 receptor antagonists
EA201200820A1 (ru) * 2009-12-08 2013-01-30 Бёрингер Ингельхайм Интернациональ Гмбх Способ синтеза промежуточных продуктов, применимых для получения замещенных индазолов и азаиндазолов
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
WO2012087782A1 (en) 2010-12-23 2012-06-28 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as ccr1 receptor antagonists
KR102268357B1 (ko) 2013-01-29 2021-06-23 아벡신 에이에스 항염증성 및 항종양성 2-옥소티아졸 및 2-옥소티오펜 화합물
WO2015157451A1 (en) * 2014-04-08 2015-10-15 Reviva Pharmaceuticals, Inc. Methods for treating attention deficit hyperactivity disorder
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
CN107206006A (zh) * 2015-01-12 2017-09-26 雷维瓦药品公司 用于治疗与帕金森病相关联的精神病的方法
WO2016115144A1 (en) * 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating alzheimer's disease
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Also Published As

Publication number Publication date
EP1201268A2 (en) 2002-05-02
EP1201268A3 (en) 2004-01-02
JP2003063994A (ja) 2003-03-05
MXPA01010872A (es) 2002-05-06
US20020052373A1 (en) 2002-05-02
CA2359877A1 (en) 2002-04-26

Similar Documents

Publication Publication Date Title
BR0104830A (pt) Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
TW200716208A (en) Modified and immediate release memantine bead formulation
GB0421639D0 (en) Methods and compositions relating to alzheimer's disease
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
GB0223040D0 (en) Therapeutic compounds
NO961326D0 (no) Inhibitorer av
RS51540B (en) MEMANTINE FOR THE TREATMENT OF Mild to Moderate Alzheimer's Disease
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
BR9914940A (pt) Método para aperfeiçoar a farmacocinética de tipranavir
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BG105302A (en) Means for improving cognition
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif
BR0311903A (pt) Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico
WO2009043858A3 (en) Methods for treating and diagnosing a cancer secreting cath-d or alzheimer's disease
BRPI0511305A (pt) método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1
BR0111102A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4pip eridinometanol ou sua pró-droga no tratamento de sintomas de demência e psicose induzida por dopamina
WO2006020852A3 (en) Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTEAO DESPACHO 8.6 DA RPI 2014 DE 11/08/2009.